- Home
- NRGV vs TLSA Comparison
NRGV vs TLSA Comparison
Compare NRGV & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRGV
- TLSA
- Stock Information
- Founded
- NRGV 2017
- TLSA 2013
- Country
- NRGV United States
- TLSA United Kingdom
- Employees
- NRGV N/A
- TLSA N/A
- Industry
- NRGV Industrial Machinery/Components
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- NRGV Miscellaneous
- TLSA Health Care
- Exchange
- NRGV Nasdaq
- TLSA Nasdaq
- Market Cap
- NRGV 190.1M
- TLSA 175.3M
- IPO Year
- NRGV N/A
- TLSA 2000
- Fundamental
- Price
- NRGV $0.81
- TLSA $1.55
- Analyst Decision
- NRGV Buy
- TLSA
- Analyst Count
- NRGV 3
- TLSA 0
- Target Price
- NRGV $1.58
- TLSA N/A
- AVG Volume (30 Days)
- NRGV 1.1M
- TLSA 282.4K
- Earning Date
- NRGV 08-05-2025
- TLSA 07-01-2025
- Dividend Yield
- NRGV N/A
- TLSA N/A
- EPS Growth
- NRGV N/A
- TLSA N/A
- EPS
- NRGV N/A
- TLSA N/A
- Revenue
- NRGV $46,974,000.00
- TLSA N/A
- Revenue This Year
- NRGV $362.17
- TLSA N/A
- Revenue Next Year
- NRGV $48.19
- TLSA N/A
- P/E Ratio
- NRGV N/A
- TLSA N/A
- Revenue Growth
- NRGV N/A
- TLSA N/A
- 52 Week Low
- NRGV $0.60
- TLSA $0.63
- 52 Week High
- NRGV $2.70
- TLSA $1.91
- Technical
- Relative Strength Index (RSI)
- NRGV 43.18
- TLSA 59.97
- Support Level
- NRGV $0.85
- TLSA $1.35
- Resistance Level
- NRGV $0.93
- TLSA $1.67
- Average True Range (ATR)
- NRGV 0.08
- TLSA 0.10
- MACD
- NRGV -0.01
- TLSA 0.02
- Stochastic Oscillator
- NRGV 3.43
- TLSA 80.88
About NRGV Energy Vault Holdings Inc.
Energy Vault Holdings Inc is a grid-scale energy storage company that is driving a faster transition to renewable power by solving the intermittence issues that are inherent to the prevalent sources of renewable energy, solar and wind. Geographical presence in United States, China and Other. Majority of its revenue comes from U.S.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.